Efficacy
GOG 240r
After a median follow up of 20.8 months, the median overall survival (OS) was 17 months in patients who received bevacizumab vs 13.3 months in patients who received chemotherapy alone (HR=0.71; CI 98% 0.54 to 0.95). In the final analysis of OS, chemotherapy plus bevacizumab continued to show a significant improvement compared with chemotherapy alone: 16.8 months versus 13.3 months (HR 0.77 [95% CI 0.62–0.95]; p=0.007). The survival benefit was evident when comparing the addition of bevacizumab to cisplatin/paclitaxel, but not significant when examining the addition of bevacizumab to topotecan/paclitaxel.
Kaplan-meier analysis of overall survival (OS)
© Lancet 2017
Quality of life (QOL) data was collected using surveys, with good compliance, and balanced between treatment groups (P=0.67). Fitted mixed-model estimates for the FACT-Cx-TOI and BPI scores indicated that the addition of bevacizumab did not adversely affect health–related quality of life.r
JCOG0505r
After a median follow up of 17.6 months, the median OS was 18.3 months in the TP group vs 17.5 months in the TC group (HR=0.994; CI 95% 16.1 to 22.9; p=0.032).
Kaplan-meier analysis of overall survival (OS)
© J Clin Oncol 2015
Post-hoc subgroup analysis in patients who had not received prior cisplatin-based chemotherapy, median OS was shorter in the TC group (13.0 months; 95% CI 10.0 to 24.0 months) than in the TP group (23.2 months; 95% CI 17.4 to 27.4 months) [HR 1.571, 95% CI 1.062 to 2.324].
In each treatment group, proportion of non-hospitalisation periods compared with planned treatment periods was assessed as an objective measure of QoL. This was significantly higher in the TC group (61.9% v 46.4%; P<0.001).